We have previously used a recombinant adenovirus vector expressing the IL-12 cytokine (Ad5IL-12) in combination with mitotane, a drug that transiently suppresses cortisol production, to enhance the activity of the vector and produce more successful therapy of experimental prostate cancers in mice [8]. The gene discussed is SPRR2A; the disease is prostate cancer.